Russia likely to face significant drug price increases in first-half 2020

17 March 2020
russia_roubles_rubles_money_big

Russia may be faced with a significant increase of drug prices in the domestic market by the end of the first quarter of the current year, which will be mainly due to the recent fall of the rouble and a potential shortage of a number of active ingredients the are used by domestic drugmakers and foreign companies operating in the local market, according to recent statements by representatives of some leading Russian pharmaceutical companies and industry’s analysts, reports The Pharma Letter’s local correspondent.

According to analysts’ predictions, the growth of prices already by the end of the current quarter may be in the range of 25%-30% on a year-on-year basis.

However, much will depend on further development of the situation in global financial markets and the dynamics of prices for Chinese active ingredients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical